Bausch Health Companies (NYSE:BHC) has been given a $30.00 price objective by stock analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday, Marketbeat.com reports. The firm currently has a “hold” rating on the stock. Royal Bank of Canada’s price target suggests a potential upside of 16.73% from the company’s previous close.
Several other research analysts have also recently weighed in on BHC. Piper Jaffray Companies set a $13.00 price target on shares of Bausch Health Companies and gave the stock a “sell” rating in a research note on Monday, July 23rd. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research note on Monday, August 6th. Mizuho reiterated a “buy” rating and set a $31.00 price target on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Cantor Fitzgerald reiterated a “buy” rating and set a $32.00 price target on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Bausch Health Companies to $18.00 and gave the company an “underweight” rating in a research note on Wednesday, August 8th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. Bausch Health Companies has an average rating of “Hold” and an average target price of $26.89.
Shares of Bausch Health Companies stock opened at $25.70 on Monday. The firm has a market cap of $8.97 billion, a PE ratio of 6.75, a price-to-earnings-growth ratio of 0.37 and a beta of -0.48. Bausch Health Companies has a 1-year low of $10.94 and a 1-year high of $28.45. The company has a debt-to-equity ratio of 6.99, a quick ratio of 0.89 and a current ratio of 1.14.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.12. The business had revenue of $2.13 billion for the quarter, compared to analysts’ expectations of $2.05 billion. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. As a group, equities analysts expect that Bausch Health Companies will post 3.47 EPS for the current fiscal year.
In other news, Director Schutter Richard U. De bought 125,000 shares of the stock in a transaction that occurred on Thursday, September 13th. The shares were bought at an average price of $23.96 per share, for a total transaction of $2,995,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Joseph C. Papa bought 30,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average price of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 165,000 shares of company stock worth $3,890,700. 11.54% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc bought a new stake in Bausch Health Companies in the 3rd quarter valued at $101,000. Point View Wealth Management Inc. bought a new stake in Bausch Health Companies in the 2nd quarter valued at $1,132,000. Marshall Wace LLP bought a new stake in Bausch Health Companies in the 2nd quarter valued at $2,974,000. Van ECK Associates Corp bought a new stake in Bausch Health Companies in the 2nd quarter valued at $11,494,000. Finally, Tobam bought a new stake in Bausch Health Companies in the 2nd quarter valued at $13,886,000. Institutional investors own 43.16% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Read More: How Do You Make Money With Penny Stocks?